Response Rates and Safety Profile

VcD VcTD VcMP

Best confirmed response rates during the treatment period

Response, % n=146 n=133 n=144

ORR (≥PR) 73 80 69

CR/nCR* 30 40 33

VGPR 7 11 7

PR 36 29 29

Safety profile during induction (I; Cycles 1–8) and during maintenance (M; Cycles 9–13)†

I (n=165) M (n=82) I (n=158) M (n=60) I (n=163) M (n=69)

Adverse events (AE), %

Grade ≥3 AEs 74 9 84 8 82 3

SAEs 48 11 53 12 47 9

Discontinuation of all study drugs due to AEs 48 58 55

On-study deaths

(treatment-related) 1 1 1

*nCR includes patients IF+ as well as patients IF- but in whom confirmatory BM biopsy was not performed†The M column represents first onset of an AE during maintenance